These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30347494)

  • 1. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
    Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
    Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
    Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
    Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
    Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
    Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
    Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR
    Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
    Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
    J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
    Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
    Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902.
    Li S; Tarlac V; Christanto RBI; French SL; Hamilton JR
    Platelets; 2021 Oct; 32(7):988-991. PubMed ID: 32819173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.
    Denorme F; Armstrong ND; Stoller ML; Portier I; Tugolukova EA; Tanner RM; Montenont E; Bhatlekar S; Cody M; Rustad JL; Ajanel A; Tolley ND; Murray DC; Boyle JL; Nieman MT; McKenzie SE; Yost CC; Lange LA; Cushman M; Irvin MR; Bray PF; Campbell RA
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37471144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
    Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
    J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
    J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
    Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
    Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
    Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
    J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
    Covic L; Gresser AL; Kuliopulos A
    Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systems biology insights into the meaning of the platelet's dual-receptor thrombin signaling.
    Sveshnikova AN; Balatskiy AV; Demianova AS; Shepelyuk TO; Shakhidzhanov SS; Balatskaya MN; Pichugin AV; Ataullakhanov FI; Panteleev MA
    J Thromb Haemost; 2016 Oct; 14(10):2045-2057. PubMed ID: 27513817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
    French SL; Thalmann C; Bray PF; Macdonald LE; Murphy AJ; Sleeman MW; Hamilton JR
    Blood Adv; 2018 Jun; 2(11):1283-1293. PubMed ID: 29884748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.